November 18, 2025 — Leads & Copy —
Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) has signed a joint venture agreement with Aiodine Laboratory Pte Ltd. to develop, test, and market Aiodine’s iodine-based disinfectant solution for chronic and acute wounds, and other antiseptic applications, according to a press release issued by Cuprina today.
The companies will focus on antiseptic wound care formulations, disinfectants, and daily home-use antiseptics, while also evaluating opportunities in personal care, oral hygiene, and veterinary applications. Clinical studies are planned to begin in 2026 to secure regulatory approvals.
Under the joint venture agreement, Cuprina will handle global sales strategies, marketing campaigns, and distribution networks. Aiodine Laboratory will contribute its proprietary iodine technology and technical expertise.
The iodine-based solution targets pathogens by attacking their amino acids, nucleotides, and fatty acids, damaging their structures and causing cell death. A study published in Wounds International evaluated the solution’s safety and efficacy in treating chronic wounds in four patients. The study at First Affiliated Hospital of Hainan Medical University found that three patients experienced significant wound healing, reduced infection, diminished inflammation, and improved tissue repair within two weeks, without toxicity or pain. The study concluded that the solution was potentially safer and more effective than current wound care solutions.
Cuprina’s Chief Executive Officer, David Quek, said the company believes the iodine-based solution is a promising treatment for severe chronic wounds and has potential applications in mouthwash and topical antiseptics. He believes this extends Cuprina’s offerings across the continuum of care.
Aiodine Laboratory Chief Technology Officer, Prof. Patrick Fernandez, PhD, said the joint venture creates a pathway to bring their iodine science to millions of patients worldwide.
According to Fortune Business Insights, the global wound care market was valued at approximately US$21 billion in 2024 and is projected to reach US$36 billion by 2032. Another study by MarketsandMarkets estimated the antiseptics and disinfectants market would exceed US$48 million by 2027.
The entire Wounds International study may be accessed at: https://woundsinternational.com/journal-articles/case-series-of-traumatic-injuries-to-evaluate-the-efficacy-and-safety-of-aiodine-in-facilitating-wound-healing/
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Scott Powell, President
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
Source: Cuprina Holdings (Cayman) Limited
